Has Bled Score Calculator

HAS-BLED intentionally mirrors CHA2DS2-VASc in format — a simple additive point score from bedside-available criteria — but answers the opposite clinical question: not whether to anticoagulate, but how much bleeding risk that anticoagulation carries once started. Its seven letters expand to hypertension (uncontrolled, systolic >160), abnormal renal or liver function (each scoring independently, up to 2 points combined), prior stroke, prior major bleeding or bleeding predisposition, labile INR (time in therapeutic range below 60% for patients on warfarin), elderly (age over 65), and drugs or alcohol (antiplatelet/NSAID use and heavy alcohol intake, each scoring independently up to 2 points). A score of 3 or higher flags 'high risk,' but guidelines are explicit that this is not meant to be used to withhold anticoagulation from patients who otherwise qualify by their stroke-risk score — the intent is to identify and correct modifiable risk factors (uncontrolled hypertension, labile INR, concurrent NSAID use, alcohol intake) and to schedule closer follow-up, since several HAS-BLED components can be actively treated. Because CHA2DS2-VASc and HAS-BLED share several overlapping risk factors (age, prior stroke, hypertension), a patient's bleeding and stroke risk often rise together, which is precisely why the score is meant to guide monitoring intensity rather than function as a gatekeeper to treatment.

Ron Pisters and colleagues developed HAS-BLED using data from the Euro Heart Survey on atrial fibrillation, publishing the derivation and validation in Chest in 2010 as a direct companion to the recently published CHA2DS2-VASc score, explicitly designed to be simple enough for routine use alongside it rather than requiring a separate specialized bleeding-risk calculator. The survey cohort included over 3,900 AF patients, allowing the authors to correlate each candidate criterion against actual major bleeding events over one year of follow-up. The score was rapidly endorsed by the 2010 and subsequent European Society of Cardiology atrial fibrillation guidelines as the preferred bleeding-risk tool to use in tandem with CHA2DS2-VASc, and Gregory Lip's follow-up analyses through the early 2010s reinforced that the score's greatest clinical value lay in identifying correctable risk factors rather than restricting anticoagulation eligibility. Competing scores (ATRIA, ORBIT, HEMORR2HAGES) were developed around the same period, but HAS-BLED's simplicity and its direct pairing with CHA2DS2-VASc kept it the most widely cited bleeding-risk tool in AF anticoagulation decision-making.